Affymetrix and Caliper Life Sciences Collaborate on Instrument Automation for Target Preparation

- Multi-Year, multi-million dollar agreement to develop and supply Sciclone and LabChip® systems for automated target preparation and processing for GeneChip® technology -

SANTA CLARA, Calif. and HOPKINTON, Mass., 13 Jan. -- Affymetrix, Inc. (Nasdaq: AFFX) and Caliper Technologies Corp. (Nasdaq: CALP), now doing business as Caliper Life Sciences, today announced a collaboration and supply agreement to develop and provide automated target preparation instruments for the GeneChip(R) Probe Array system, the new High Throughput Array (HTA) system and future GeneChip platforms. These new automation systems are expected to substantially reduce array processing time, reduce variability and labor costs, and enable researchers to industrialize their genomic research.

The two companies will develop products that leverage Caliper's expertise in high-throughput automation and microfluidics with Affymetrix' expertise in microarray technology and applications. The first products are expected to be launched later this year and will automate GeneChip microarray target preparation steps including hybridization, washing and staining for expression analysis. The automated system will enable a single operator to run up to 96 RNA samples at a time, compared to the current manual rate of 20 to 24 samples.

"We're extremely pleased to partner with Caliper Life Sciences, a recognized leader in liquid handling, automation and microfluidics, to provide robust industrial solutions and standardization of genomics processes," said Trevor Nicholls, Chief Commercial Officer, Global Operations at Affymetrix. "We view this as a critical next step in our goal of industrializing microarray technology to further increase efficiency and quality of results."

Affymetrix will market and distribute the line of automation products developed under the multi-year agreement. Caliper will serve as an OEM provider and partner with Affymetrix to provide installation, training and field support for these new automated systems.

"The announcement of this agreement, just as we launch our company under the new name, Caliper Life Sciences, is a testament to the excitement that we are generating, and to the ability of our new management team to systematically identify and seal important business development relationships," said Kevin Hrusovsky, President and CEO at Caliper. "An important component of our new company's strategy is to find key partners who will help us further propel our laboratory automation and microfluidics technologies into the life sciences industry. As a pioneer and leader in this industry, Affymetrix is an ideal partner to help us achieve that goal."

Future Affymetrix/Caliper projects will focus on developing new platforms for gene expression and DNA analysis that utilize Caliper's microfluidics technology and expertise.

About Caliper Life Sciences:

Caliper Life Sciences uses its advanced liquid handling and LabChip® technologies to create leading edge tools that accelerate drug discovery and enhance the diagnosis of disease. Caliper headquarters are located in Hopkinton, Massachusetts, with R&D, operations and manufacturing facilities for LabChip devices in Mountain View, California, and direct sales, service and applications support throughout the world. Caliper customers and partners include many of the largest pharmaceutical, biotechnology, and life sciences companies. For more information, please visit Caliper's web site at www.caliperLS.com.

About Affymetrix:

Affymetrix is a pioneer in creating breakthrough tools that are driving the genomic revolution. By applying the principles of semiconductor technology to the life sciences, Affymetrix develops and commercializes systems that enable scientists to improve the quality of life. The Company's customers include pharmaceutical, biotechnology, agrichemical, diagnostics and consumer products companies as well as academic, government and other non-profit research institutes. Affymetrix offers an expanding portfolio of integrated products and services, including its integrated GeneChip® platform, to address growing markets focused on understanding the relationship between genes and human health. Additional information on Affymetrix can be found at www.affymetrix.com.

The statements in this press release regarding events and results to occur in the future are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding the development of new products for automating high throughput target preparation systems and the launching of such products later in 2004, and the development of new platforms for gene expression and DNA analysis. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Caliper from those projected, including, but not limited to, the risk of unexpected delays in completing the development of these new products and the risk that the demand for these products may not be as strong as presently anticipated. These and other risk factors are discussed under the caption "Factors Affecting Operating Results" in Caliper's Annual Report on Form 10-K for the year ended December 31, 2002, and in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2003, filed with the Securities and Exchange Commission on November 14, 2003. Caliper expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Caliper's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

All statements in this press release that are not historical are "forward- looking statements" within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix' "expectations," "beliefs," "hopes," "intentions," "strategies" or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including, but not limited to risks of the Company's ability to achieve and sustain higher levels of revenue, higher gross margins, reduced operating expenses, uncertainties relating to technological approaches, manufacturing, product development, market acceptance (including uncertainties relating to this collaboration), personnel retention, uncertainties related to cost and pricing of Affymetrix products, dependence on collaborative partners, uncertainties relating to sole source suppliers, uncertainties relating to FDA and other regulatory approvals, competition, risks relating to intellectual property of others and the uncertainties of patent protection and litigation. These and other risk factors are discussed in Affymetrix' Form 10-K for the year ended December 31, 2002 and other SEC reports, including its Quarterly Reports on Form 10-Q for subsequent quarterly periods. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Affymetrix' expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

NOTE: LabChip is a registered trademark of Caliper Technologies Corp.

Affymetrix, the Affymetrix logo, and GeneChip are registered trademarks owned or used by Affymetrix, Inc.

For further information, please contact:

Sue Charles, CEO Northbank Communications, +44 (0)20 7886 8152, s.charles@northbankcommunications.com

Wes Conard, Senior Manager of Public Relations, +1 (0)408 731 5791